{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.\n\nalemtuzumab\n\nbusulfan\n\ncyclophosphamide\n\nmethotrexate\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG000","title":"Alemtuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 100 days","title":"Grades III-IV Acute Graft-vs-host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Participants"}